Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioAge Labs, Inc. (NASDAQ: BIOA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on metabolic diseases and aging biology, BioAge uses these filings to report financial results, describe its pipeline, and outline material developments in its business.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of research and development spending, collaboration revenue, cash and marketable securities, and risk factors related to clinical trials and regulatory processes. Current reports on Form 8-K include earnings press releases, such as those announcing results for specific quarters, and other material events that the company chooses to highlight.
For a company like BioAge, which is advancing BGE-102, an NLRP3 inhibitor for obesity and cardiovascular risk factors, and preclinical APJ agonist programs for obesity, SEC filings provide context on how these programs are funded and prioritized. Management’s discussion and analysis sections describe progress in clinical trials, preclinical work, and collaborations with partners such as Novartis and Lilly ExploR&D, as well as associated costs.
On Stock Titan, users can access these filings alongside AI-powered summaries that explain key points in plain language. Real-time updates from the EDGAR system ensure that new 10-K, 10-Q, and 8-K filings appear promptly, while Form 4 insider transaction reports and proxy statements, when filed, can be used to track executive and director share activity and governance topics. This page helps readers navigate BioAge’s regulatory record without needing to parse every technical detail themselves.
BioAge Labs, Inc. is conducting a primary offering of 5,897,435 shares of common stock at $19.50 per share, with gross proceeds of about $115.0 million and estimated net proceeds of about $107.6 million. Underwriters have a 30‑day option to buy up to 884,615 additional shares, which would raise net proceeds to roughly $123.9 million if fully exercised.
The company is a clinical‑stage biopharmaceutical developer focused on metabolic diseases, led by its NLRP3 inhibitor BGE‑102 and APJ agonist programs for obesity. As of September 30, 2025, it had 35,850,037 shares outstanding, which would rise to 41,747,472 shares after this offering (excluding the option). BioAge estimates it held about $285.1 million in cash, cash equivalents and marketable securities as of December 31, 2025.
Net proceeds, together with existing cash, are intended to fund research, clinical and process development and manufacturing for BGE‑102 and its NLRP3 and APJ programs, as well as working capital, capital expenditures, debt repayment and other general corporate purposes. Based on current plans, BioAge believes this funding, combined with its existing balance, will support operations and capital needs through 2029, though it may still seek additional capital in the future.
BioAge Labs, Inc. CFO Dov A. Goldstein reported an option exercise and related stock acquisition. On January 16, 2026, he exercised a stock option for 3,542 shares of common stock at an exercise price of $4.38 per share, coded as an "M" transaction.
The derivative table shows this option carried a conversion price of $4.38 and an expiration date of February 17, 2035. Following the transaction, Goldstein held 25,950 shares of BioAge common stock directly and 166,458 stock options directly. The option vests in equal monthly installments of 1/48th of the total award, starting on February 1, 2025, contingent on continued service.
BioAge Labs, Inc. is offering $75,000,000 of its common stock in a primary public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $11,250,000 of shares. The company’s stock trades on the Nasdaq Global Select Market under the symbol “BIOA.” BioAge is a clinical-stage biopharmaceutical company focused on metabolic diseases such as obesity, led by BGE-102, an orally available, brain-penetrant NLRP3 inhibitor now in a Phase 1 SAD/MAD trial, and APJ agonist programs targeting obesity with oral and injectable candidates. As of December 31, 2025, BioAge preliminarily estimates $285.1 million in cash, cash equivalents and marketable securities, and currently expects existing cash plus offering proceeds to fund operations and capital needs through 2029. Net proceeds are intended mainly for research, clinical and manufacturing activities for BGE-102 and the NLRP3 and APJ programs, as well as working capital and general corporate purposes.
BioAge Labs, Inc. filed a current report describing an indication expansion for its oral NLRP3 inhibitor BGE-102 and outlining upcoming clinical milestones. The company plans to start a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026.
In a preclinical DME model, oral BGE-102 showed dose-dependent preservation of retinal vascular integrity, with near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity. BGE-102 has shown favorable tolerability to date in an ongoing Phase 1 trial, alongside robust reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β.
The development plan includes completing the Phase 1 trial with full data in the first half of 2026, starting a Phase 2a proof-of-concept trial in obesity with cardiovascular risk factors in the first half of 2026, initiating the DME Phase 1b/2a trial in mid-2026, and targeting data readouts for the cardiovascular trial in the second half of 2026 and for the DME trial in mid-2027.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported an option exercise and related share sales. On 01/13/2026 he exercised a stock option for 27,000 shares of common stock at an exercise price of $8.39 per share, increasing his directly held common stock to 49,408 shares and leaving 92,587 stock options beneficially owned.
On the same date, he sold an aggregate of 27,000 common shares in multiple transactions at weighted average prices of $18.4278, $19.4526, $20.5392 and $21.0808 per share, leaving 22,408 common shares beneficially owned directly. The filing notes these trades were executed pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2024, and that the option vests in 1/48th monthly installments beginning May 17, 2024, with an early exercise feature.
BioAge Labs, Inc. Chief Executive Officer and director Kristen Fortney reported selling 233,107 shares of the company’s common stock on January 13, 2026. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 21, 2024, which is designed to allow insiders to systematically trade shares over time.
The shares were sold at a weighted average price of $18.1163 per share, with individual sale prices ranging from $18.00 to $18.385 per share. After this transaction, Fortney beneficially owns 976,949 shares of BioAge Labs common stock in direct ownership.
A holder of BioAge Labs, Inc. common stock has filed a notice under Rule 144 to sell 233,107 shares of common stock through Raymond James & Associates on the NASDAQ, with an approximate sale date of 01/13/2026. The filing lists an aggregate market value of these planned sales of $4,195,926.00 and states that 35,855,037 shares of the issuer’s common stock are outstanding.
The shares to be sold relate to a prior restricted stock purchase dated 08/14/2015, when 1,210,056 common shares were acquired from BioAge Labs, Inc. and paid for by check. By signing the notice, the person for whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s operations that has not been publicly disclosed.
BIOA filed a Form 144 notice for a planned sale of 27,000 shares of its common stock. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $531,828.03. The filing notes that 35,855,037 shares of the issuer’s common stock are outstanding. The 27,000 shares were acquired on 01/13/2026 through the cash exercise of an option that was granted on 04/17/2024.
BioAge Labs, Inc. reported additional positive interim Phase 1 results for BGE-102, a novel brain-penetrant NLRP3 inhibitor being tested in people with obesity and elevated cardiovascular risk. In the first multiple ascending dose cohort, participants receiving 120 mg once daily showed rapid and marked anti-inflammatory effects, including an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized hsCRP levels below 2 mg/L.
BGE-102 also produced significant reductions in IL-6 and fibrinogen, two biomarkers linked to systemic inflammation and cardiovascular events, and was described as well tolerated with a favorable safety profile. The company highlighted a newly issued patent covering additional composition of matter and a novel NLRP3 binding site. Planned milestones include completing the Phase 1 trial and initiating a Phase 2a proof-of-concept study in the first half of 2026, followed by Phase 2a data in the second half of 2026.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin reported option exercises and a share sale. On January 2, 2026, he exercised stock options to acquire 5,433 common shares at $4.11 per share and 2,000 common shares at $6.57 per share. On the same day he sold 7,433 common shares at a weighted average price of $12.8468 per share, with individual sale prices ranging from $12.571 to $13.242. Following these transactions, he directly held no shares of common stock but continued to hold stock options, including 16,303 options at $4.11 and 7,383 options at $6.57. The activity was carried out under a Rule 10b5-1 trading plan adopted on November 5, 2024.